{
    "nct_id": "NCT04207944",
    "official_title": "Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)",
    "inclusion_criteria": "1. Subject is a man or woman between the ages of 21 and 85 (inclusive) years.\n2. Subject has high-risk IPMN as defined below.\n\n   1. Patient (previously resected) has undergone partial pancreatectomy for non-invasive IPMN AND has new or residual cyst(s) > 1 cm and/or\n   2. Patient (not previously resected) has a radiographic lesion of the pancreas consistent with IPMN as documented by: Cyst fluid CEA > 192 ng/ml OR presence of GNAS or RNF 43 mutation noted in cyst fluid OR MRI imaging confirmation of \"likely\", \"probable\" or \"confirmed\" communication with main pancreatic duct\n\n   AND at least one of the following worrisome features:\n   * Cyst > 2.5 cm\n   * Thickened/enhancing cyst walls\n   * Main pancreatic duct > 5mm\n   * Abrupt change in caliber of pancreatic duct with distal atrophy\n3. Subjects has ECOG of 0-2\n4. Subject is medically fit to undergo EUS.\n5. Female subjects who are of childbearing potential or are capable of becoming pregnant must be willing to use appropriate methods of contraception for the length of the study.\n6. Subject is able to provide written informed consent.\nHealthy volunteers allowed\nMust have minimum age of 21 Years\nMust have maximum age of 85 Years",
    "exclusion_criteria": "1. Subject has pathologic evidence of pancreatic adenocarcinoma.\n2. Subject takes a systemic corticosteroid or NSAID more than 3 times per week.\n3. Subject has a known history of or currently existing allergy to NSAIDs, aspirin induced asthma, gastric ulcers, non-iatrogenic intestinal perforation, or gastrointestinal bleeding from NSAID usage for which intervention was required..\n4. Subject has an ongoing history of renal insufficiency (eGFR <50 mL/minute/1.73 m2), cardiovascular disease, gastrointestinal disorder, or any other condition that serves as a contraindication to the use of sulindac in the opinion of the treating investigator.\n5. Myocardial infarction or coronary artery bypass grafting within six months of study entry.\n6. Diagnosis of Congestive Heart Failure.\n7. Severe adverse drug reaction to contrast agents that cannot be managed with routine premedication prior to imaging.\n8. Diagnosis for (other) prior malignancy (except in situ and non-melanoma skin cancers) and are actively receiving antineoplastic or immuno therapy within 90 days of randomization.\n9. History of medical procedure that would prevent an endoscopic ultrasound from being performed (such as Roux-en-Y, prior total gastrectomy).\n10. Subject is lactating or pregnant.",
    "miscellaneous_criteria": ""
}